PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 28, 2024Antimicrobial Agents and Chemotherapy42 citationsOpen Access

Effect of modification of penicillin-binding protein 3 on susceptibility to ceftazidime-avibactam, imipenem-relebactam, meropenem-vaborbactam, aztreonam-avibactam, cefepime-taniborbactam, and cefiderocol of Escherichia coli strains producing broad-spectrum β-lactamases

View Full Paper
CTChristophe Le TerrierUniversity of GenevaPNPatrice NordmannUniversité Paris-SudCBChloé BuchsUniversity of Fribourg

Key Points

Key points are not available for this paper at this time.

Abstract

ABSTRACT The impact of penicillin-binding protein 3 (PBP3) modifications that may be identified in Escherichia coli was evaluated with respect to susceptibility to β-lactam/β-lactamase inhibitor combinations including ceftazidime-avibactam, imipenem-relebactam, meropenem-vaborbactam, aztreonam-avibactam, cefepime-taniborbactam, and to cefiderocol. A large series of E. coli recombinant strains producing broad-spectrum β-lactamases was evaluated. While imipenem-relebactam showed a similar activity regardless of the PBP3 background, susceptibility to other molecules tested was affected at various levels. This was particularly the case for ceftazidime-avibactam, aztreonam-avibactam, and cefepime-taniborbactam.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Terrier et al. (2024) studied this question.

synapsesocial.com/papers/68e770a2b6db6435876e6758https://doi.org/10.1128/aac.01548-23
Ask AI
Helpful
Bookmark
Share
View Full Paper